Dr Erba on the webcast presentation at ASH didnt make really any issue of safety at all....and it was on dec5th i believe (recently). allo transplant setting is rife with fatality as is sadly, so perhaps it s not 33a related directly yet fda fully held that one and partially held the two trials next on the risk 'table' to make sure? we can only be fumbling in the dark though for sure. of note, the press release did emphasize that 33a has treated over 300 patients so far. hopefully a positive hint from siegall as he didnt have to include that fact.
News 
Market Data 
Discover 
